Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tazemetostat Rollover Study (TRuST)
NCT02875548Phase 2Terminated
- Sponsor
- Epizyme, Inc.
- Start
- Aug 2016
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of tazemetostat in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), synovial sarcoma (SS), epithelioid sarcoma (ES), mesothelioma, sponsored by Epizyme, Inc.. Started Aug 2016; status: terminated.
02
Drugs
tazemetostat
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)synovial sarcoma (SS)epithelioid sarcoma (ES)mesothelioma
Beyond the preview
Go deeper on NCT02875548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02875548.